S

Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581

Watchlist Manager
Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581
Watchlist
Price: 11.88 CNY -5.64% Market Closed
Market Cap: 7.8B CNY
Have any thoughts about
Shandong Sinobioway Biomedicine Co Ltd?
Write Note

Shandong Sinobioway Biomedicine Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shandong Sinobioway Biomedicine Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
S
Shandong Sinobioway Biomedicine Co Ltd
SZSE:002581
Cash from Operating Activities
-ÂĄ29.3m
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Fufeng Group Ltd
HKEX:546
Cash from Operating Activities
ÂĄ3.3B
CAGR 3-Years
251%
CAGR 5-Years
13%
CAGR 10-Years
N/A
G
GHW International
HKEX:9933
Cash from Operating Activities
ÂĄ120.1m
CAGR 3-Years
N/A
CAGR 5-Years
43%
CAGR 10-Years
N/A
Ningxia Baofeng Energy Group Co Ltd
SSE:600989
Cash from Operating Activities
ÂĄ8.8B
CAGR 3-Years
13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhejiang XinAn Chemical Industrial Group Co Ltd
SSE:600596
Cash from Operating Activities
ÂĄ471.8m
CAGR 3-Years
-40%
CAGR 5-Years
-10%
CAGR 10-Years
4%
A
Anhui Jinhe Industrial Co Ltd
SZSE:002597
Cash from Operating Activities
ÂĄ866m
CAGR 3-Years
-6%
CAGR 5-Years
-1%
CAGR 10-Years
12%
No Stocks Found

Shandong Sinobioway Biomedicine Co Ltd
Glance View

Market Cap
7.8B CNY
Industry
Chemicals

Shandong Sinobioway Biomedicine Co., Ltd. engages in the research and development, manufacture, and sale of chemical raw materials, chemical and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 653 full-time employees. The company went IPO on 2011-05-20. The firm's main products include encyclopedia, anferon, triethyl orthoformate, trimethyl orthofomate, trimethyl orthoacetate and related secondary products, among others. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
3.08 CNY
Overvaluation 74%
Intrinsic Value
Price
S

See Also

What is Shandong Sinobioway Biomedicine Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
-29.3m CNY

Based on the financial report for Jun 30, 2024, Shandong Sinobioway Biomedicine Co Ltd's Cash from Operating Activities amounts to -29.3m CNY.

What is Shandong Sinobioway Biomedicine Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
4%

Over the last year, the Cash from Operating Activities growth was 69%. The average annual Cash from Operating Activities growth rates for Shandong Sinobioway Biomedicine Co Ltd have been 4% over the past three years .

Back to Top